Posted by Michael Wonder on 18 Mar 2025
Cellphire Therapeutics CLPH-511 fast track designation granted
17 March 2025 - Cellphire Therapeutics today announced that the US FDA has granted fast track designation for CLPH-511 (frozen activated platelets) injectable suspension for the treatment of acute haemorrhage as an alternative to conventional platelets when not available or in short supply.
